Table of Contents

1 Study Coverage

• 1.1 Human Vaccine Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Human Vaccine Market Size Growth Rate by Product
  • 1.4.2 Varicella
  • 1.4.3 Influenza
  • 1.4.4 Polio
  • 1.4.5 Hepatitis A
  • 1.4.6 Rabies
  • 1.4.7 BCG
  • 1.4.8 Hepatitis B
  • 1.4.9 Pertussis, Diphtheria, Tetanus
  • 1.4.10 Pneumococcal
  • 1.4.11 Rota vaccine
• 1.5 Market by End User
  • 1.5.1 Global Human Vaccine Market Size Growth Rate by End User
  • 1.5.2 Adults
  • 1.5.3 Children
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Human Vaccine Market Size
  • 2.1.1 Global Human Vaccine Revenue 2014-2025
  • 2.1.2 Global Human Vaccine Sales 2014-2025
• 2.2 Human Vaccine Growth Rate by Regions
  • 2.2.1 Global Human Vaccine Sales by Regions
  • 2.2.2 Global Human Vaccine Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Human Vaccine Sales by Manufacturers
  • 3.1.1 Human Vaccine Sales by Manufacturers
  • 3.1.2 Human Vaccine Sales Market Share by Manufacturers
  • 3.1.3 Global Human Vaccine Market Concentration Ratio (CR5 and HHI)
• 3.2 Human Vaccine Revenue by Manufacturers
  • 3.2.1 Human Vaccine Revenue by Manufacturers (2014-2019)
  • 3.2.2 Human Vaccine Revenue Share by Manufacturers (2014-2019)
• 3.3 Human Vaccine Price by Manufacturers
• 3.4 Human Vaccine Manufacturing Base Distribution, Product Types
  • 3.4.1 Human Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Human Vaccine Product Type
  • 3.4.3 Date of International Manufacturers Enter into Human Vaccine Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Human Vaccine Sales by Product
• 4.2 Global Human Vaccine Revenue by Product
• 4.3 Human Vaccine Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Human Vaccine Breakdown Data by End User

6 North America

• 6.1 North America Human Vaccine by Countries
  • 6.1.1 North America Human Vaccine Sales by Countries
  • 6.1.2 North America Human Vaccine Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Human Vaccine by Product
• 6.3 North America Human Vaccine by End User

7 Europe

• 7.1 Europe Human Vaccine by Countries
  • 7.1.1 Europe Human Vaccine Sales by Countries
  • 7.1.2 Europe Human Vaccine Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Human Vaccine by Product
• 7.3 Europe Human Vaccine by End User

8 Asia Pacific

• 8.1 Asia Pacific Human Vaccine by Countries
  • 8.1.1 Asia Pacific Human Vaccine Sales by Countries
  • 8.1.2 Asia Pacific Human Vaccine Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Human Vaccine by Product
• 8.3 Asia Pacific Human Vaccine by End User

9 Central & South America

• 9.1 Central & South America Human Vaccine by Countries
  • 9.1.1 Central & South America Human Vaccine Sales by Countries
  • 9.1.2 Central & South America Human Vaccine Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Human Vaccine by Product
• 9.3 Central & South America Human Vaccine by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Human Vaccine by Countries
  • 10.1.1 Middle East and Africa Human Vaccine Sales by Countries
  • 10.1.2 Middle East and Africa Human Vaccine Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Human Vaccine by Product
• 10.3 Middle East and Africa Human Vaccine by End User

11 Company Profiles

• 11.1 CNBG
  • 11.1.1 CNBG Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 CNBG Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 CNBG Human Vaccine Products Offered
  • 11.1.5 CNBG Recent Development
• 11.2 Changsheng Life
  • 11.2.1 Changsheng Life Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Changsheng Life Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Changsheng Life Human Vaccine Products Offered
  • 11.2.5 Changsheng Life Recent Development
• 11.3 Zhifei
  • 11.3.1 Zhifei Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Zhifei Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Zhifei Human Vaccine Products Offered
  • 11.3.5 Zhifei Recent Development
• 11.4 ChengDa Bio
  • 11.4.1 ChengDa Bio Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 ChengDa Bio Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 ChengDa Bio Human Vaccine Products Offered
  • 11.4.5 ChengDa Bio Recent Development
• 11.5 Kangtai
  • 11.5.1 Kangtai Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Kangtai Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Kangtai Human Vaccine Products Offered
  • 11.5.5 Kangtai Recent Development
• 11.6 SINOVAC BIOTECH
  • 11.6.1 SINOVAC BIOTECH Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 SINOVAC BIOTECH Human Vaccine Products Offered
  • 11.6.5 SINOVAC BIOTECH Recent Development
• 11.7 Hissen
  • 11.7.1 Hissen Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Hissen Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Hissen Human Vaccine Products Offered
  • 11.7.5 Hissen Recent Development
• 11.8 Walvax Biotechnology
  • 11.8.1 Walvax Biotechnology Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Walvax Biotechnology Human Vaccine Products Offered
  • 11.8.5 Walvax Biotechnology Recent Development
• 11.9 GSK
  • 11.9.1 GSK Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 GSK Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 GSK Human Vaccine Products Offered
  • 11.9.5 GSK Recent Development
• 11.10 SANOFI
  • 11.10.1 SANOFI Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 SANOFI Human Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 SANOFI Human Vaccine Products Offered
  • 11.10.5 SANOFI Recent Development
• 11.11 Rong An
• 11.12 NuoCheng Bio
• 11.13 Hualan Bio
• 11.14 Tiantan biological
• 11.15 Changchun Baike
• 11.16 Adimmune
• 11.17 Zhongyianke Biotech

12 Future Forecast

• 12.1 Human Vaccine Market Forecast by Regions
  • 12.1.1 Global Human Vaccine Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Human Vaccine Revenue Forecast by Regions 2019-2025
• 12.2 Human Vaccine Market Forecast by Product
  • 12.2.1 Global Human Vaccine Sales Forecast by Product 2019-2025
  • 12.2.2 Global Human Vaccine Revenue Forecast by Product 2019-2025
• 12.3 Human Vaccine Market Forecast by End User
• 12.4 North America Human Vaccine Forecast
• 12.5 Europe Human Vaccine Forecast
• 12.6 Asia Pacific Human Vaccine Forecast
• 12.7 Central & South America Human Vaccine Forecast
• 12.8 Middle East and Africa Human Vaccine Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Human Vaccine Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
China Human Vaccine is widely used for adults and children. The most proportion of China Human Vaccine is children, and the sales market share in 2017 is 64.6%.
The classification of China Human Vaccine includes Varicella, Influenza, Polio, Hepatitis A, Rabies, BCG, Hepatitis B, Pertussis, Diphtheria, Tetanus, Pneumococcal, Rota vaccine and other kinds of vaccines, and the proportion of Rabies in 2017 is about 20.4%.
The global Human Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Human Vaccine market based on company, product type, end user and key regions.

This report studies the global market size of Human Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Human Vaccine in these regions.
This research report categorizes the global Human Vaccine market by top players/brands, region, type and end user. This report also studies the global Human Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech

Market size by Product
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Rota vaccine
Market size by End User
Adults
Children

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Human Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Human Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Human Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Human Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Human Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (M Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Human Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.